Zimmer Biomet (ZBH) SVP Lori Winkler Sells 1,500 Shares at $104

Lori Winkler, Senior Vice President and CHRO of Zimmer Biomet Holdings, reported sales of common stock on September 8, 2025.

Rhea-AI Filing Summary

Lori Winkler, Senior Vice President and CHRO of Zimmer Biomet Holdings, reported sales of common stock on September 8, 2025. The Form 4 discloses 1,500 shares sold at a weighted average price of $104.15 per share (individual sale prices ranged from $104.15 to $104.18). After the transactions, Ms. Winkler beneficially owns 6,833 shares, held directly. The sale was reported on the Form 4 filed September 10, 2025, and was executed by an attorney-in-fact on her behalf.

Insights

Securities Analyst

Routine insider sale; small size relative to typical executive holdings, likely neutral.

The Form 4 shows a direct sale of 1,500 shares by the company CHRO at a weighted average price of $104.15, reducing direct beneficial ownership to 6,833 shares. The filing includes an explanatory note that the sale occurred in multiple transactions on September 8, 2025, and affirms availability of detailed pricing per lot upon request. There is no indication in the filing of any plan-based transaction (no 10b5-1 box checked), no amendment to prior filings, and no derivative activity reported. As presented, this appears to be a routine disposition rather than a material corporate event.

Corporate Governance Expert

Disclosure complies with Section 16 timing; no governance red flags apparent from this filing alone.

The Form 4 is signed by an attorney-in-fact and contains the required explanatory footnote about weighted average pricing across multiple lots. Reporting identifies the filer as an officer (SVP and CHRO) and indicates direct ownership form. The report does not reference plans or exemptions that would change the interpretation of the sale. From a governance and compliance perspective, the filing meets disclosure requirements and does not reveal related-party transactions or other governance concerns within the document.

Insider Trade Summary

Net Seller: 1,500 shares

Net Sell 1 txn

Insider Winkler Lori

Role SVP and CHRO

Sold 1,500 shs ($156K)

Type	Security	Shares	Price	Value
Sale	Common Stock	1,500	$104.15	$156K

Holdings After Transaction: Common Stock — 6,833 shares (Direct)

Footnotes (1)

1. F1. Reflects the weighted average price of 1,500 common shares sold by the reporting person in multiple transactions on September 8, 2025 with sale prices ranging from $104.15 to $104.18 per share. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price.

FAQ

What did Lori Winkler sell according to the ZBH Form 4?

The Form 4 reports Ms. Winkler sold 1,500 shares of Zimmer Biomet common stock on September 8, 2025.

At what price were the ZBH shares sold by Lori Winkler?

The weighted average sale price was $104.15 per share, with individual sale prices ranging from $104.15 to $104.18.

How many ZBH shares does Lori Winkler own after the sale?

After the reported transactions, Ms. Winkler beneficially owns 6,833 shares, held directly.

When was the Form 4 for these transactions filed?

The Form 4 reporting these transactions was dated and signed on September 10, 2025.

Was this sale part of a 10b5-1 trading plan according to the filing?

The filing does not indicate that the transaction was made pursuant to a 10b5-1 plan (no plan box is checked).

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 09/10/2025 - 04:16 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Winkler Lori

(Last) (First) (Middle)

345 E. MAIN STREET

(Street)

WARSAW IN 46580

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
ZIMMER BIOMET HOLDINGS, INC. [ ZBH ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	SVP and CHRO

3. Date of Earliest Transaction (Month/Day/Year)
09/08/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/08/2025		S		1,500	D	$104.15(1)	6,833	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Reflects the weighted average price of 1,500 common shares sold by the reporting person in multiple transactions on September 8, 2025 with sale prices ranging from $104.15 to $104.18 per share. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price.

	/s/ Matthew R. St. Louis, Attorney-in-Fact for Lori Winkler (power of attorney previously filed)	09/10/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.